Option Bulls Could Accelerate a GW Pharmaceuticals PLC (GWPH) 'Breakdown'

One analyst claims GW Pharmaceuticals PLC - ADR (NASDAQ:GWPH) stock is "on the brink of a technical breakdown"

Alex Eppstein
Aug 11, 2016 at 2:45 PM
    facebook twitter linkedin


    GW Pharmaceuticals PLC - ADR (NASDAQ:GWPH) attracted attention this morning when the U.S. Drug Enforcement Administration (DEA) said marijuana will remain an illegal Schedule 1 substance due to lingering questions about its medical efficacy. GWPH, which is developing a cannabis-based epilepsy treatmenthas previously warned of DEA-related delays for its drug to reach the U.S. market, but today's news was generally considered a positive for scientists and researchers.*

    Earlier, the stock was down by as much as 2.4%, but at last check, is off only 0.2% at $86.38. Still, that didn't stop one analyst from suggesting GWPH shares are "on the brink of a technical breakdown," as they approach their supportive $85 level -- since there are few other potential footholds until the round $70 area. That lower level also corresponds with GWPH's lows following its mid-March bull gap.

    gwph daily august 11

    The aforementioned technical analysis could be exacerbated by high levels of optimism. GWPH's 50-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) call/put volume ratio is 1.76 -- just 10 percentage points from an annual peak. In other words, traders have bought to open calls over puts at a historically accelerated clip.

    Plus, the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.85 sits in the call-skewed 1st percentile of its annual range. From a contrarian perspective, an unwinding of this optimism could result in headwinds.

    Another potential bad omen is the recent decline we've seen in GWPH short interest. Specifically, short interest fell 18% during the most recent reporting period. However, if the shares breach $85 and start speeding toward $70, a resumption in short selling could catalyze the losses.

    Last but not least, five of six analysts rate GW Pharmaceuticals PLC - ADR (NASDAQ:GWPH) a "buy" or better. This leaves the door wide open for a future round of downgrades, which could trigger even more selling activity.

    *Editor's note: The original text of this article included an inaccurate report of GWPH's response to the DEA ruling. We regret the error.
     

    Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.


    A Schaeffer's exclusive!

    The Expert's Guide

    Access your FREE trading earnings guide for Q3 before it's too late!


      
     

    Partnercenter